All In Biotech

Drug Trial Radar · NCT01163149

Safety and Efficacy Study of Asfotase Alfa in Adolescents and Adults With Hypophosphatasia (HPP)

A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control Study of the Safety, Efficacy, Pharmacokinetic of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults With Hypophosphatasia (HPP)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

19

Actual

Start

Jun 2010

Primary completion

Jun 2016

Study completion Jun 2016

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Jul 15, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 13 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This clinical trial was conducted to study hypophosphatasia (HPP), a bone disorder caused by gene mutations or changes. These gene mutations cause low levels of an enzyme needed to harden bone. The purpose of this study was to test the safety and efficacy of two doses of the study drug called asfotase alfa as compared to a control group to see effects on adolescents and adults with HPP.

Conditions

  • Hypophosphatasia

Interventions

  • asfotase alfaDrug

    Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)

  • asfotase alfaDrug

    Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 24 for Plasma Pyridoxal-5' Phosphate (PLP)Time frame: Baseline, Week 24
  2. Change From Baseline to Week 24 for Plasma Inorganic Pyrophosphate (PPi)Time frame: Baseline, Week 24
  3. Safety and Tolerability of Asfotase AlfaTime frame: Up to 288 weeks exposure to asfotase alfa

Locations

3 sites in 2 countries. Site status is shown where the registry gives one.

  • Shriner's Hospital for Children

    St Louis, Missouri

  • Duke University Medical Center

    Durham, North Carolina

  • Health Sciences Centre Winnipeg, University of Manitoba

    Winnipeg, Manitoba, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.